Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    NCT00932893
Show Display Options
Download search resultsDownload the search results for:
NCT00932893 (1 records)
Download Content:
Zip file readers with free trial periods: WinZip or PKZip
Rank Status Study
1 Active, not recruiting
Has Results
An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: PF-02341066;   Drug: Pemetrexed;   Drug: Docetaxel

Indicates status has not been verified in more than two years